Richard Saynor named new Sandoz CEO

24 April 2019
sandoz-logo-big

Novartis (NOVN: VX) has raided GlaxoSmithKline (LSE: GSK) to replace the departed chief executive of the Swiss drugmaker’s Sandoz generics unit.

Richard Saynor, currently the UK pharma major’s senior vice president for classic and established products, commercial and digital platforms, will replace Richard Francis, who left his role at Sandoz in March.

Mr Saynor’s 20 years in the industry has given him experience with both generics and established pharmaceutical brands, and before joining GSK, he held commercial operations leadership roles at Sandoz and oversaw an expansion of its generics business across Asia, Latin America and Turkey.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics